Desonide NDC 24470-920

NDC codes

FDA NDC Directory

Product NDC (as listed)24470-920Labeler and product segments. Claims need a package NDC.

Product NDC at billing width24470-0920Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
24470-920-60	24470092060	1 TUBE in 1 CARTON (24470-920-60) / 60 g in 1 TUBEMarketed from Jul 9, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Desonide
Generic name (nonproprietary): desonide
Active ingredients: Desonide — .5 mg/g
Dosage form: Gel
Route: Topical
Labeler: Cintex Services, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 202470
Marketing start: Jul 9, 2020
Listing expires: Dec 31, 2026
Other FDA classes: Corticosteroid Hormone Receptor Agonists (Mechanism)
Identifiers: Product ID 24470-920_abbf5cd6-1be7-100a-e053-2a95a90a8b7aSPL ID abbf5cd6-1be7-100a-e053-2a95a90a8b7aSPL set ID a6192416-09b4-47fa-e053-2a95a90add96RxCUI 669081UNII J280872D1O
Pharmacologic class: Corticosteroid

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Topical products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N424470092060 followed by a unit qualifier and the quantity

Package 24470-0920-60. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 31, 2020.

Indications (excerpt from the label)

Desonide Gel, 0.05% is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Patients should be instructed to use Desonide Gel, 0.05% for the minimum amount of time as necessary to achieve the desired results because of the potential for Desonide Gel, 0.05% to suppress the hypothalamicpituitary-adrenal (HPA) axis [see Warnings and Precautions ( 5.1 )]. Treatment should not exceed 4 consecutive weeks [see Dosage and Administration ( 2 )]. Desonide Gel, 0.05% is a corticosteroid indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)